Suchergebnisse - "Weis, Nina"

PubPharm (13)

1

Pre-existing, treatment-specific resistance-associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct-acting antivirals

enthalten in: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica | 2023

von Sølund, C. | Pedersen, M. | Fahnøe, U. | +5

2

Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals : a clinical randomized study

enthalten in: European journal of gastroenterology & hepatology | 2018

von Sølund, C. | Andersen, E. | Mössner, B. | +10

3

Inducible protein-10 as a predictive marker of antiviral hepatitis C treatment : A systematic review

enthalten in: World journal of hepatology | 2017

von Neesgaard, B. | Ruhwald, M. | Weis, N.

4

Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study

enthalten in: PloS one | 2017

von Dalgard, O. | Weiland, O. | Noraberg, G. | +14

5

The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease

enthalten in: BMC infectious diseases | 2017

von Young, J. | Weis, N. | Hofer, H. | +11

6

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection : a randomised study

enthalten in: Gut | 2015

von Hézode, C. | Hirschfield, G. | Ghesquiere, W. | +31

7

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY) : a randomised, open-label phase 2 trial

enthalten in: Lancet (London, England) | 2015

von Sulkowski, M. | Hezode, C. | Gerstoft, J. | +20

CommentIn: Lancet. 2015 Mar 21;385(9973):1050-2. - PMID 25468162

8

Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection

enthalten in: Gastroenterology | 2015

von Dore, G. | Lawitz, E. | Hézode, C. | +24

9

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study

enthalten in: Gut | 2015

von Hézode, C. | Hirschfield, G. | Ghesquiere, W. | +31

10

Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses : lack of correlation to treatment outcome

enthalten in: PloS one | 2013

von Pedersen, J. | Jensen, T. | Carlsen, T. | +6